Literature DB >> 16156716

Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury.

Dunyue Lu1, Asim Mahmood, Changsheng Qu, Anton Goussev, Timothy Schallert, Michael Chopp.   

Abstract

Erythropoietin (EPO) is neuroprotective in models of stroke and traumatic brain injury (TBI) when administered prior to or within the first few hours after injury. We seek to demonstrate that EPO also has neurorestorative effects when administered late (i.e., 1 day) after TBI in the rat. Twelve rats were subjected to TBI. Six rats were treated with EPO daily for 14 days starting 1 day after injury, and an additional six rats were treated with saline. Bromodeoxyuridine (BrdU) was administered daily for 14 days. Memory tests using a Morris Water Maze were performed prior to and after injury and treatment. Animals were sacrificed at 15 days after TBI, and their brains were prepared for histological analysis of damage to the dentate gyrus (DG) and for evaluation of newly formed neurons using double labeling of BrdU and MAP-2. The data revealed a significant improvement in spatial memory and significant increase in the number of newly formed neurons with EPO treatment compared with control animals. These data suggest that EPO treatment initiated 1 day after TBI is neurorestorative by enhancing neurogenesis, as well as neuroprotective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156716     DOI: 10.1089/neu.2005.22.1011

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  95 in total

1.  Thymosin beta4: a candidate for treatment of stroke?

Authors:  Daniel C Morris; Michael Chopp; Li Zhang; Zheng G Zhang
Journal:  Ann N Y Acad Sci       Date:  2010-04       Impact factor: 5.691

2.  Pharmacologic amelioration of severe hypoglycemia-induced neuronal damage.

Authors:  Julie M Silverstein; Daniel Musikantow; Erwin C Puente; Dorit Daphna-Iken; Adam J Bree; Simon J Fisher
Journal:  Neurosci Lett       Date:  2011-01-25       Impact factor: 3.046

3.  Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke.

Authors:  D C Morris; M Chopp; L Zhang; M Lu; Z G Zhang
Journal:  Neuroscience       Date:  2010-08-25       Impact factor: 3.590

4.  Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury.

Authors:  Ye Xiong; Asim Mahmood; Yanlu Zhang; Yuling Meng; Zheng Gang Zhang; Changsheng Qu; Thomas N Sager; Michael Chopp
Journal:  J Neurosurg       Date:  2010-11-12       Impact factor: 5.115

Review 5.  Angiogenesis, neurogenesis and brain recovery of function following injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Curr Opin Investig Drugs       Date:  2010-03

6.  Red Blood Cell Transfusion and Transfusion Alternatives in Traumatic Brain Injury.

Authors:  Andreas H Kramer; Peter Le Roux
Journal:  Curr Treat Options Neurol       Date:  2012-02-08       Impact factor: 3.598

7.  Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats.

Authors:  Yuling Meng; Ye Xiong; Asim Mahmood; Yanlu Zhang; Changsheng Qu; Michael Chopp
Journal:  J Neurosurg       Date:  2011-04-15       Impact factor: 5.115

8.  Role of gender in outcome after traumatic brain injury and therapeutic effect of erythropoietin in mice.

Authors:  Ye Xiong; Asim Mahmood; Dunyue Lu; Changsheng Qu; Anton Goussev; Timothy Schallert; Michael Chopp
Journal:  Brain Res       Date:  2007-10-31       Impact factor: 3.252

Review 9.  Endogenous neurogenic cell response in the mature mammalian brain following traumatic injury.

Authors:  Dong Sun
Journal:  Exp Neurol       Date:  2015-04-30       Impact factor: 5.330

Review 10.  Animal models of traumatic brain injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Nat Rev Neurosci       Date:  2013-02       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.